Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Allele- and tir-independent functions of intimin in diverse animal infection models.

Mallick EM, Brady MJ, Luperchio SA, Vanguri VK, Magoun L, Liu H, Sheppard BJ, Mukherjee J, Donohue-Rolfe A, Tzipori S, Leong JM, Schauer DB.

Front Microbiol. 2012 Jan 31;3:11. doi: 10.3389/fmicb.2012.00011. eCollection 2012.

2.

Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host.

Brady MJ, Radhakrishnan P, Liu H, Magoun L, Murphy KC, Mukherjee J, Donohue-Rolfe A, Tzipori S, Leong JM.

Front Microbiol. 2011 Nov 15;2:226. doi: 10.3389/fmicb.2011.00226. eCollection 2011.

3.

In vivo versus in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals changes in the expression of proteins involved in virulence, stress and energy metabolism.

Kuntumalla S, Zhang Q, Braisted JC, Fleischmann RD, Peterson SN, Donohue-Rolfe A, Tzipori S, Pieper R.

BMC Microbiol. 2011 Jun 24;11:147. doi: 10.1186/1471-2180-11-147.

4.

The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins.

Pieper R, Zhang Q, Parmar PP, Huang ST, Clark DJ, Alami H, Donohue-Rolfe A, Fleischmann RD, Peterson SN, Tzipori S.

Proteomics. 2009 Nov;9(22):5029-45. doi: 10.1002/pmic.200900196.

5.

Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome.

Kuntumalla S, Braisted JC, Huang ST, Parmar PP, Clark DJ, Alami H, Zhang Q, Donohue-Rolfe A, Tzipori S, Fleischmann RD, Peterson SN, Pieper R.

Proteome Sci. 2009 Jun 29;7:22. doi: 10.1186/1477-5956-7-22.

6.

Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection.

Zhang Q, Donohue-Rolfe A, Krautz-Peterson G, Sevo M, Parry N, Abeijon C, Tzipori S.

J Infect Dis. 2009 Feb 15;199(4):486-93. doi: 10.1086/596509.

7.

EspFU, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7.

Ritchie JM, Brady MJ, Riley KN, Ho TD, Campellone KG, Herman IM, Donohue-Rolfe A, Tzipori S, Waldor MK, Leong JM.

Cell Microbiol. 2008 Apr;10(4):836-47. Epub 2007 Dec 6.

8.

Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7.

Campellone KG, Roe AJ, Løbner-Olesen A, Murphy KC, Magoun L, Brady MJ, Donohue-Rolfe A, Tzipori S, Gally DL, Leong JM, Marinus MG.

Mol Microbiol. 2007 Mar;63(5):1468-81.

9.

Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.

Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2005 Aug;73(8):4607-13.

10.

Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells.

Akiyoshi DE, Rich CM, O'Sullivan-Murphy S, Richard L, Dilo J, Donohue-Rolfe A, Sheoran AS, Chapman-Bonofiglio S, Tzipori S.

Infect Immun. 2005 Jul;73(7):4054-61.

11.

Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H.

Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents. Review.

12.

Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2003 Jun;71(6):3125-30.

13.

Production and characterization of protective human antibodies against Shiga toxin 1.

Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2002 Oct;70(10):5896-9.

14.

Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2002 Feb;70(2):612-9.

15.

Localization of the binding site for the oligosaccharide moiety of Gb3 on verotoxin 1 using NMR residual dipolar coupling measurements.

Thompson GS, Shimizu H, Homans SW, Donohue-Rolfe A.

Biochemistry. 2000 Oct 31;39(43):13153-6.

PMID:
11052667
16.
17.

Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.

Konadu E, Donohue-Rolfe A, Calderwood SB, Pozsgay V, Shiloach J, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):6191-3.

18.

Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.

Donohue-Rolfe A, Kondova I, Mukherjee J, Chios K, Hutto D, Tzipori S.

Infect Immun. 1999 Jul;67(7):3645-8.

19.

Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens.

Fuchs S, Mühldorfer I, Donohue-Rolfe A, Kerényi M, Emödy L, Alexiev R, Nenkov P, Hacker J.

Microb Pathog. 1999 Jul;27(1):13-23.

PMID:
10371706
20.
21.

Construction and characterization of an isogenic slt-ii deletion mutant of enterohemorrhagic Escherichia coli.

Gunzer F, Bohn U, Fuchs S, Mühldorfer I, Hacker J, Tzipori S, Donohue-Rolfe A.

Infect Immun. 1998 May;66(5):2337-41.

22.

Solution structure of the carbohydrate-binding B-subunit homopentamer of verotoxin VT-1 from E. coli.

Richardson JM, Evans PD, Homans SW, Donohue-Rolfe A.

Nat Struct Biol. 1997 Mar;4(3):190-3. No abstract available.

PMID:
9164458
23.

Characterization of Escherichia coli strains isolated from environmental water habitats and from stool samples of healthy volunteers.

Mühldorfer I, Blum G, Donohue-Rolfe A, Heier H, Olschläger T, Tschäpe H, Wallner U, Hacker J.

Res Microbiol. 1996 Oct;147(8):625-35.

PMID:
9157489
24.

Regulation of the Shiga-like toxin II operon in Escherichia coli.

Mühldorfer I, Hacker J, Keusch GT, Acheson DW, Tschäpe H, Kane AV, Ritter A, Olschläger T, Donohue-Rolfe A.

Infect Immun. 1996 Feb;64(2):495-502.

25.

Purification of subunit B of Shiga toxin using a synthetic trisaccharide-based affinity matrix.

Pozsgay V, Trinh L, Shiloach J, Robbins JB, Donohue-Rolfe A, Calderwood SB.

Bioconjug Chem. 1996 Jan-Feb;7(1):45-55. Erratum in: Bioconjug Chem 1996 Jul-Aug;7(4):523.

PMID:
8741990
26.

Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells.

Jacewicz MS, Acheson DW, Mobassaleh M, Donohue-Rolfe A, Balasubramanian KA, Keusch GT.

J Clin Invest. 1995 Sep;96(3):1328-35.

27.

The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection.

Tzipori S, Gunzer F, Donnenberg MS, de Montigny L, Kaper JB, Donohue-Rolfe A.

Infect Immun. 1995 Sep;63(9):3621-7.

28.

Inhibition of Shiga-like toxins by brefeldin A.

Donta ST, Tomicic TK, Donohue-Rolfe A.

J Infect Dis. 1995 Mar;171(3):721-4.

PMID:
7876627
29.

Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e.

Keusch GT, Jacewicz M, Acheson DW, Donohue-Rolfe A, Kane AV, McCluer RH.

Infect Immun. 1995 Mar;63(3):1138-41.

30.

Expression and purification of Shiga-like toxin II B subunits.

Acheson DW, De Breucker SA, Jacewicz M, Lincicome LL, Donohue-Rolfe A, Kane AV, Keusch GT.

Infect Immun. 1995 Jan;63(1):301-8.

31.

Mitomycin immunoblot colony assay for detection of Shiga-like toxin-producing Escherichia coli in fecal samples: comparison with DNA probes.

Hull AE, Acheson DW, Echeverria P, Donohue-Rolfe A, Keusch GT.

J Clin Microbiol. 1993 May;31(5):1167-72.

32.

Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systems.

Acheson DW, Calderwood SB, Boyko SA, Lincicome LL, Kane AV, Donohue-Rolfe A, Keusch GT.

Infect Immun. 1993 Mar;61(3):1098-104.

33.

One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays.

Acheson DW, Jacewicz M, Kane AV, Donohue-Rolfe A, Keusch GT.

Microb Pathog. 1993 Jan;14(1):57-66.

PMID:
8321118
34.

Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.

Levine MM, McEwen J, Losonsky G, Reymann M, Harari I, Brown JE, Taylor DN, Donohue-Rolfe A, Cohen D, Bennish M, et al.

J Clin Microbiol. 1992 Jul;30(7):1636-41.

35.
36.

Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis.

O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT.

Curr Top Microbiol Immunol. 1992;180:65-94. Review. No abstract available.

PMID:
1324134
37.

Crystallization of the B chain of Shiga-like toxin I from Escherichia coli.

Hart PJ, Monzingo AF, Donohue-Rolfe A, Keusch GT, Calderwood SB, Robertus JD.

J Mol Biol. 1991 Apr 20;218(4):691-4.

PMID:
2023244
38.

Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects.

Keusch GT, Jacewicz M, Mobassaleh M, Donohue-Rolfe A.

Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S304-10. Review.

PMID:
2047654
39.

Shiga toxin: purification, structure, and function.

Donohue-Rolfe A, Acheson DW, Keusch GT.

Rev Infect Dis. 1991 Mar-Apr;13 Suppl 4:S293-7. Review.

PMID:
2047652
40.

A system for production and rapid purification of large amounts of the Shiga toxin/Shiga-like toxin I B subunit.

Calderwood SB, Acheson DW, Goldberg MB, Boyko SA, Donohue-Rolfe A.

Infect Immun. 1990 Sep;58(9):2977-82.

41.

Construction and analysis of TnphoA mutants of enteropathogenic Escherichia coli unable to invade HEp-2 cells.

Donnenberg MS, Calderwood SB, Donohue-Rolfe A, Keusch GT, Kaper JB.

Infect Immun. 1990 Jun;58(6):1565-71.

42.

A comparison of HEp-2 cell invasion by enteropathogenic and enteroinvasive Escherichia coli.

Donnenberg MS, Donohue-Rolfe A, Keusch GT.

FEMS Microbiol Lett. 1990 May;57(1-2):83-6.

PMID:
2199306
43.

Enzyme-linked immunosorbent assay for Shiga toxin and Shiga-like toxin II using P1 glycoprotein from hydatid cysts.

Acheson DW, Keusch GT, Lightowlers M, Donohue-Rolfe A.

J Infect Dis. 1990 Jan;161(1):134-7.

PMID:
2295845
45.

Cancer-associated hemolytic uremic syndrome: a possible role of mitomycin in relation to Shiga-like toxins.

Acheson DW, Donohue-Rolfe A.

J Clin Oncol. 1989 Dec;7(12):1943. No abstract available.

PMID:
2511278
47.

Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin.

Donohue-Rolfe A, Jacewicz M, Keusch GT.

Mol Microbiol. 1989 Sep;3(9):1231-6.

PMID:
2677606
48.
49.
50.

Pathogenesis of Shigella diarrhea. XIV. Analysis of Shiga toxin receptors on cloned HeLa cells.

Jacewicz M, Feldman HA, Donohue-Rolfe A, Balasubramanian KA, Keusch GT.

J Infect Dis. 1989 May;159(5):881-9.

PMID:
2651533

Supplemental Content

Loading ...
Support Center